# Use of Wharton Jelly in Diabetic Nephropathy

> **NCT03288571** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sophia Al-Adwan** · enrollment: 20 (estimated)

## Conditions studied

- Diabetic Nephropathies

## Interventions

- **BIOLOGICAL:** Wharton Jelly Mesenchymal stem cells

## Key facts

- **NCT ID:** NCT03288571
- **Lead sponsor:** Sophia Al-Adwan
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11
- **Primary completion:** 2020-12
- **Final completion:** 2021-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-07-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03288571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03288571, "Use of Wharton Jelly in Diabetic Nephropathy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03288571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*